7 Aptamers for Personalized Therapeutics
201
23. Davydova A, Vorobyeva M, Bashmakova E, Vorobjev P, Krasheninina O, Tupikin A, Kabilov
M, Krasitskaya V, Frank L, Venyaminova A (2019) Development and characterization of
novel 2 -F-RNA aptamers specific to human total and glycated hemoglobins. Anal Biochem
570:43–50
24. Fechter P, Da Silva EC, Mercier M-C, Noulet F, Etienne-Seloum N, Guenot D, Lehmann
M, Vauchelles R, Martin S, Lelong-Rebel I (2019) RNA aptamers targeting integrin α5β1 as
probes for cyto-and histofluorescence in Glioblastoma. Mol Ther Nucleic Acids 17:63–77
25. Radko S, Rakhmetova SY, Bodoev N, Archakov A (2007) Aptamers as affinity reagents for
clinical proteomics. Biochem (Moscow) Suppl Ser B Biomed Chem 1(3):198–209
26. Zhou G, Latchoumanin O, Hebbard L, Duan W, Liddle C, George J, Qiao L (2018) Aptamers
as targeting ligands and therapeutic molecules for overcoming drug resistance in cancers. Adv
Drug Deliv Rev 134:107–121
27. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO (2009) Discovery and development of
the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86(3):151–
164
28. Bates PJ, Reyes-Reyes EM, Malik MT, Murphy EM, O’toole MG, Trent JO (2017) Gquadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms.
Biochimica et Biophysica Acta (BBA)-General Subjects 1861(5):1414–1428
29. Reyes-Reyes EM, Šalipur FR, Shams M, Forsthoefel MK, Bates PJ (2015) Mechanistic studies
of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation.
Mol Oncol 9(7):1392–1405
30. Baba SA, Mutreja R, Beniwal A, Jain S, Yadav E, Ghosh T, Navani NK, Kumar P (2019)
Nucleic acid guided molecular tool for in-vivo theranostic applications. In: Aptamers.
Springer, pp 101–122
31. Kallio P, Jokinen E, Högström J, Das S, Heino S, Lähde M, Brodkin J, Korhonen EA, Alitalo
K (2020) Blocking angiopoietin-2 promotes vascular damage and growth inhibition in mouse
tumors treated with small doses of radiation. Can Res 80(12):2639–2650
32. Vandghanooni S, Eskandani M, Barar J, Omidi Y (2019) Aptamedicine: a new treatment
modality in personalized cancer therapy. BioImpacts: BI 9 (2):67
33. Stavridi F, Karapanagiotou EM, Syrigos KN (2010) Targeted therapeutic approaches for
hormone-refractory prostate cancer. Cancer Treat Rev 36(2):122–130
34. Wang Y, Luo Y, Bing T, Chen Z, Lu M, Zhang N, Shangguan D, Gao X (2014) DNA aptamer
evolved by cell-SELEX for recognition of prostate cancer. PLoS ONE 9(6):e100243
35. Bing T, Wang J, Shen L, Liu X, Shangguan D (2020) Prion Protein Targeted by a prostate
cancer cell binding aptamer, a potential tumor marker? ACS Appl Bio Mater 3(5):2545–2552
36. Camp RL, Dolled-Filhart M, King BL, Rimm DL (2003) Quantitative analysis of breast cancer
tissue microarrays shows that both high and normal levels of HER2 expression are associated
with poor outcome. Can Res 63(7):1445–1448
37. Burris HA III, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE,
Michaelson RA, Girish S (2011) Phase II study of the antibody drug conjugate trastuzumabDM1 for the treatment of human epidermal growth factor receptor 2 (HER2)–positive breast
cancer after prior HER2-directed therapy. J Clin Oncol 29(4):398–405
38. Moosavian SA, Jaafari MR, Taghdisi SM, Mosaffa F, Badiee A, Abnous K (2015) Development of RNA aptamers as molecular probes for HER2+ breast cancer study using cell-SELEX.
Iran J Basic Med Sci 18(6):576
39. Tang Z, Jun Y, Lv Y, Li Y, Zhang Z, Tao M, Chen X, He J, Zhang L, Wang Q-L (2020)
Aptamer-conjugated and doxorubicin-loaded grapefruit-derived nanovectors for targeted
therapy against HER2+ breast cancer. J Drug Target 28(2):186–194
40. Wu Q, Wu L, Wang Y, Zhu Z, Song Y, Tan Y, Wang X-F, Li J, Kang D, Yang CJ (2016)
Evolution of DNA aptamers for malignant brain tumor gliosarcoma cell recognition and
clinical tissue imaging. Biosens Bioelectron 80:1–8
41. Wu Q, Lin N, Tian T, Zhu Z, Wu L, Wang H, Wang D, Kang D, Tian R, Yang C (2019)
Evolution of nucleic acid aptamers capable of specifically targeting glioma stem cells via
cell-SELEX. Anal Chem 91(13):8070–8077
201
23. Davydova A, Vorobyeva M, Bashmakova E, Vorobjev P, Krasheninina O, Tupikin A, Kabilov
M, Krasitskaya V, Frank L, Venyaminova A (2019) Development and characterization of
novel 2 -F-RNA aptamers specific to human total and glycated hemoglobins. Anal Biochem
570:43–50
24. Fechter P, Da Silva EC, Mercier M-C, Noulet F, Etienne-Seloum N, Guenot D, Lehmann
M, Vauchelles R, Martin S, Lelong-Rebel I (2019) RNA aptamers targeting integrin α5β1 as
probes for cyto-and histofluorescence in Glioblastoma. Mol Ther Nucleic Acids 17:63–77
25. Radko S, Rakhmetova SY, Bodoev N, Archakov A (2007) Aptamers as affinity reagents for
clinical proteomics. Biochem (Moscow) Suppl Ser B Biomed Chem 1(3):198–209
26. Zhou G, Latchoumanin O, Hebbard L, Duan W, Liddle C, George J, Qiao L (2018) Aptamers
as targeting ligands and therapeutic molecules for overcoming drug resistance in cancers. Adv
Drug Deliv Rev 134:107–121
27. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO (2009) Discovery and development of
the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86(3):151–
164
28. Bates PJ, Reyes-Reyes EM, Malik MT, Murphy EM, O’toole MG, Trent JO (2017) Gquadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms.
Biochimica et Biophysica Acta (BBA)-General Subjects 1861(5):1414–1428
29. Reyes-Reyes EM, Šalipur FR, Shams M, Forsthoefel MK, Bates PJ (2015) Mechanistic studies
of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation.
Mol Oncol 9(7):1392–1405
30. Baba SA, Mutreja R, Beniwal A, Jain S, Yadav E, Ghosh T, Navani NK, Kumar P (2019)
Nucleic acid guided molecular tool for in-vivo theranostic applications. In: Aptamers.
Springer, pp 101–122
31. Kallio P, Jokinen E, Högström J, Das S, Heino S, Lähde M, Brodkin J, Korhonen EA, Alitalo
K (2020) Blocking angiopoietin-2 promotes vascular damage and growth inhibition in mouse
tumors treated with small doses of radiation. Can Res 80(12):2639–2650
32. Vandghanooni S, Eskandani M, Barar J, Omidi Y (2019) Aptamedicine: a new treatment
modality in personalized cancer therapy. BioImpacts: BI 9 (2):67
33. Stavridi F, Karapanagiotou EM, Syrigos KN (2010) Targeted therapeutic approaches for
hormone-refractory prostate cancer. Cancer Treat Rev 36(2):122–130
34. Wang Y, Luo Y, Bing T, Chen Z, Lu M, Zhang N, Shangguan D, Gao X (2014) DNA aptamer
evolved by cell-SELEX for recognition of prostate cancer. PLoS ONE 9(6):e100243
35. Bing T, Wang J, Shen L, Liu X, Shangguan D (2020) Prion Protein Targeted by a prostate
cancer cell binding aptamer, a potential tumor marker? ACS Appl Bio Mater 3(5):2545–2552
36. Camp RL, Dolled-Filhart M, King BL, Rimm DL (2003) Quantitative analysis of breast cancer
tissue microarrays shows that both high and normal levels of HER2 expression are associated
with poor outcome. Can Res 63(7):1445–1448
37. Burris HA III, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE,
Michaelson RA, Girish S (2011) Phase II study of the antibody drug conjugate trastuzumabDM1 for the treatment of human epidermal growth factor receptor 2 (HER2)–positive breast
cancer after prior HER2-directed therapy. J Clin Oncol 29(4):398–405
38. Moosavian SA, Jaafari MR, Taghdisi SM, Mosaffa F, Badiee A, Abnous K (2015) Development of RNA aptamers as molecular probes for HER2+ breast cancer study using cell-SELEX.
Iran J Basic Med Sci 18(6):576
39. Tang Z, Jun Y, Lv Y, Li Y, Zhang Z, Tao M, Chen X, He J, Zhang L, Wang Q-L (2020)
Aptamer-conjugated and doxorubicin-loaded grapefruit-derived nanovectors for targeted
therapy against HER2+ breast cancer. J Drug Target 28(2):186–194
40. Wu Q, Wu L, Wang Y, Zhu Z, Song Y, Tan Y, Wang X-F, Li J, Kang D, Yang CJ (2016)
Evolution of DNA aptamers for malignant brain tumor gliosarcoma cell recognition and
clinical tissue imaging. Biosens Bioelectron 80:1–8
41. Wu Q, Lin N, Tian T, Zhu Z, Wu L, Wang H, Wang D, Kang D, Tian R, Yang C (2019)
Evolution of nucleic acid aptamers capable of specifically targeting glioma stem cells via
cell-SELEX. Anal Chem 91(13):8070–8077